S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
NYSEAMERICAN:HEB

Hemispherx BioPharma Stock Forecast, Price & News

$2.26
-0.08 (-3.42 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.22
Now: $2.26
$2.38
50-Day Range N/A
52-Week Range
$1.69
Now: $2.26
$14.81
Volume1.46 million shs
Average Volume102,599 shs
Market Capitalization$5.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Hemispherx BioPharma logo

Headlines

Hemispherx Biopharma EPS beats by $0.65
August 15, 2019 |  seekingalpha.com
Hemispherx down 21% on stock sales deal
July 22, 2019 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:HEB
CUSIPN/A
Phone+1-407-2718516
Employees31
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$5.52 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1608th out of 1,968 stocks

Biotechnology Industry

86th out of 125 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$2.26
-0.08 (-3.42 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HEB News and Ratings via Email

Sign-up to receive the latest news and ratings for HEB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions

What stocks does MarketBeat like better than Hemispherx BioPharma?

Wall Street analysts have given Hemispherx BioPharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hemispherx BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter.
View Hemispherx BioPharma's earnings history
.

When did Hemispherx BioPharma's stock split? How did Hemispherx BioPharma's stock split work?

Hemispherx BioPharma's stock reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of Hemispherx BioPharma stock prior to the reverse split would have 2 shares after the split.

Who are Hemispherx BioPharma's key executives?

Hemispherx BioPharma's management team includes the following people:
  • Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)
  • Mr. Adam Pascale, Chief Financial Officer (Age 71)
  • Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)
  • Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)
  • Ms. Ellen Lintal, Chief Accounting Officer

Who are some of Hemispherx BioPharma's key competitors?

What other stocks do shareholders of Hemispherx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Biocept (BIOC), (GDPMQ) (GDPMQ), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN), Biopharmx (BPMX), CTI BioPharma (CTIC), Advaxis (ADXS), Cytori Therapeutics (CYTX) and Frontier Communications (FTR).

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

How do I buy shares of Hemispherx BioPharma?

Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hemispherx BioPharma's stock price today?

One share of HEB stock can currently be purchased for approximately $2.26.

How much money does Hemispherx BioPharma make?

Hemispherx BioPharma has a market capitalization of $5.52 million.

How many employees does Hemispherx BioPharma have?

Hemispherx BioPharma employs 31 workers across the globe.

What is Hemispherx BioPharma's official website?

The official website for Hemispherx BioPharma is www.hemispherx.net.

Where are Hemispherx BioPharma's headquarters?

Hemispherx BioPharma is headquartered at 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States.

How can I contact Hemispherx BioPharma?

Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.